zolbetuximab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Trial Timeline
Oct 18, 2019 → Jan 22, 2021
NCT ID
NCT04086758About zolbetuximab
zolbetuximab is a phase 1 stage product being developed by Astellas Pharma for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04086758. Target conditions include Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06048081 | Pre-clinical | Active |
| NCT06902545 | Pre-clinical | Recruiting |
| NCT04086758 | Phase 1 | Completed |
| NCT03528629 | Pre-clinical | Completed |
Competing Products
20 competing products in Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma